Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Learn more about:
Related Clinical Trial
Clinical Precise Diagnosis and Treatment in the Kawasaki Disease A Blood Test to Diagnose Kawasaki Disease Defibrotide in Children With High Risk Kawasaki Disease Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease A Randomized Phase III Multicenter Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease Statins Study in Kawasaki Disease Children With Coronary Artery Abnormalities Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Prevention of Coronary Aneurysms in Kawasaki Syndrome A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Anakinra and Kawasaki Disease Study of Combined Therapy of Aspirin and “IVIG-SN” in Kawasaki Disease Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease Cardiovascular Status of Children 5 Years After Kawasaki Disease Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD. A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease Etanercept in Kawasaki Disease Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Infliximab (Remicade) for Patients With Acute Kawasaki Disease Acute Abdomen in Kawasaki Disease Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017 Different Doses of IVIG for Kawasaki Disease Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 Measurement of Antibodies in Adults With a History of Kawasaki Disease Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Genetic Determinants of Kawasaki Disease Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Brief Title

Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Official Title

Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Brief Summary

      Kawasaki disease (KD) is an acute multi-system vasculitis syndrome of unknown etiology
      occurring mostly in infants and children younger than 5 years of age. In developed countries,
      it is the leading cause of acquired heart disease in children. However, KD remains a
      mysterious disease.

      Single high dose intravenous immunoglobulin (IVIG, 2gm/kg) and aspirin are standard treatment
      for KD. Aspirin have been prescribed in treatment of KD for decade even earlier than usage of
      IVIG. High dose aspirin mainly act as anti-inflammation, while low dose aspirin as
      anti-platelet. IVIG may play most of the role of anti-inflammation in acute stage of KD.
      Hsieh et al. reported that KD without high dose aspirin had the same treatment response after
      IVIG. Therefore it is still unclear about the necessarily of high dose aspirin in acute stage
      of KD.

      This study was conduct to investigate the role of high dose aspirin in acute stage of KD via
      a multi-center randomized control trail, and we plan to achieve the followings till year
      2017:

        1. Enroll 300 KD patients from multiple medical centers . Randomize group patients as group
           1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low
           dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute
           febrile stage, only use low dose aspirin (N=150).

        2. Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT,
           BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate
           (followed at least 1 year).
    

Detailed Description

      All subjects are children who fulfilled the criteria for KD and who are treated with IVIG at
      each hospital after informed contents are obtained. The patients are initially treated with a
      single dose of IVIG (2 g/kg) during a 12-hour period.

      Principal clinical features of KD that occur in the acute stage within 5 days of the onset of
      fever will be recorded. After the informed content from the parents, PB samples will be
      obtained before IVIG treatment (pre-IVIG, KD1), within 3 days after complete initial IVIG
      treatment (post-IVIG, KD2) as the acute stage samples and then 1 month, 6 month and 12 month
      followed-up as subacute/convalescent stage samples. CAL was defined as the internal diameter
      being at least 3 mm of the coronary artery (4 mm if the subject was over the age of 5 years)
      or the internal diameter of a segment at least 1.5 times as large as that of an adjacent
      segment by echocardiogram.

      High dose aspirin will be given (> 30 mg/kg/day) until the fever subsided at group 1
      randomly. After fever subside (<38C, for 48 hours) low-dose aspirin (3-5 mg/kg/day) will be
      prescribed for all patients until all signs of inflammation resolved in both group 1 and 2.
    


Study Type

Interventional


Primary Outcome

To assess total hospital day

Secondary Outcome

 To assess total fever duration

Condition

Kawasaki Disease

Intervention

Aspirin

Study Arms / Comparison Groups

 with high dose aspirin
Description:  KD patients treated with high dose IVIG (2gm/kg) and high dose aspirin (>50mg/kg/day) since diagnosed, then taper to low dose aspirin (3-5mg/kg/day) when fever subside.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

300

Start Date

May 2013

Completion Date

April 2017

Primary Completion Date

April 2017

Eligibility Criteria

        Inclusion Criteria: (both 1 and 2)

        1. All subjects are children who fulfilled the criteria for Kawasaki Disease (American
        Heart Association criteria).

          1. Fever > 5 days, and 4 of the 5 following symptoms

          2. Diffuse mucosal inflammation (strawberry tongue, dry and fissured lips)

          3. Bilateral non-purulent conjunctivitis,

          4. Dysmorphous skin rashes,

          5. Indurative angioedema over the hands and feet

          6. Cervical lymphadenopathy. (One or more nodule at lease 1.5 cm in diameter) 2. KD
             patients are treated with IVIG at each hospital after informed contents are obtained.

        Exclusion Criteria:

          1. Patients whose symptoms did not full fit the Kawasaki Disease criteria.

          2. Had an acute fever for < 5 days and >10 days

          3. Incomplete collection of each followed-up data (CBC/DC, GOT/GPT, BUN/Cr, Albumin, ESR,
             C-Reactive Protein, 2D echocardiography)

          4. IVIG treatment at other hospital before refers to study centers.

          5. Treatment with corticosteroids, other than inhaled forms, in the previous 2 weeks
             before enrollment;

          6. The presence of a disease known to mimic Kawasaki disease.

          7. Previous diagnosis of Kawasaki disease

          8. Inability to take aspirin
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Ho-Chang Kuo, MD, PhD, , 



Administrative Informations


NCT ID

NCT02359643

Organization ID

Kawasaki Disease


Responsible Party

Sponsor

Study Sponsor

Chang Gung Memorial Hospital


Study Sponsor

Ho-Chang Kuo, MD, PhD, Study Chair, Chang Gung Memorial Hospital


Verification Date

May 2013